Icarus Consultants

Icarus Consultants to attend ASCO 2013 in Chicago

Daedalus — Tue, 21 May 2013 19:33:20 +0000

The 2013 annual meeting of the American Society of Clinical Oncology (ASCO) is fast approaching, and for many in cancer drug development, it is one of the landmarks of the year. For those clients and potential clients interested in learning more about our capabilities or discussing our services, we will be in Chicago for ASCO – please do contact us if you would like to meet up.

Pharma Strategy Report on Chimeric Antigen Receptor Technology CART available to download

Daedalus — Tue, 21 May 2013 14:43:34 +0000

To celebrate the launch of Pharma Strategy Reports, we are offering a complimentary executive summary on Chimeric Antigen Receptor Technology (CART), written by Sally Church, PhD.

The challenge of Tumor Lysis Syndrome in Hematology New Product Development

Daedalus — Wed, 20 Feb 2013 13:04:17 +0000

Tumor Lysis Syndrome (TLS) has been in the news recently as a result of two patient deaths in a chronic lymphocytic leukemia (CLL) clinical trial with AbbVie’s ABT-199, a novel BCL-2 inhibitor in early stages of development. What is TLS and why is this important in cancer research was subsequently analyzed by Icarus Consultants hematology industry expert, Sally Church, PhD on Pharma Strategy Blog.

What prostate clinical trial would you do if given a million dollars?

Daedalus — Tue, 19 Feb 2013 12:35:42 +0000

At the recent American Society of Clinical Oncology Genitourinary cancers symposium in Orlando (ASCO GU), Sally Church, PhD interviewed Professor Bertrand Tombal about some of the latest clinical research in prostate cancer. In the interview, Professor Tombal says what prostate cancer clinical trial he would like to do if you gave him a million dollars.

Pancreatic Cancer Market changes with Abraxane

Daedalus — Mon, 18 Feb 2013 12:19:05 +0000

Celgene Corporation's nab-paclitaxel (Abraxane) will be a new treatment for advanced pancreatic cancer. That was the news from the 2013 American Society of Clinical Oncology Gastrointestinal Cancers symposium (ASCO GI) that took place in San Francisco last month. Where we expect Abraxane is likely to receive most pancreatic cancer use in the United States is from community oncologists who don’t wish to manage the side effects associated with FOLFIRINOX.

Seek Insights not Data Dumps

Daedalus — Mon, 28 Jan 2013 21:16:43 +0000

Data is now commoditized. While obtaining data is relatively easy, insights are a lot more expensive and difficult to generate. Why? They require the application of knowledge, deep understanding and expertise of the topic to analyze, conceptualize and visualize data, and then extrapolate what it means to a company or product. Making sense of data is what we do.

New for 2013: Oncology New Products Senior Executive Coaching Program

Daedalus — Mon, 31 Dec 2012 23:48:37 +0000

Publicly available for the first time in 2013, this annual "New Products MBA" program involves custom monthly case studies and 1:1 coaching. It is designed for senior executives with responsibility for new product development or those involved with strategic decision making in this area.

The Challenges of Multiple Myeloma Market Research

Daedalus — Thu, 29 Nov 2012 13:45:01 +0000

Multiple Myeloma (MM) is forecast to be a hot topic at the forthcoming annual meeting of the American Society of Hematology (ASH) that starts in Atlanta next week. Based on our experience, multiple myeloma is a challenging topic for pharma market research.

Sally Church in FierceBiotech Top 50 Voices in Biotech Twittersphere

Daedalus — Mon, 26 Nov 2012 15:48:30 +0000

Icarus Consultants EVP Sally Church, PhD included in the FierceBiotech Top 50 Voices in Biotech Twittersphere. Good to see Sally recognized for her industry expertise, knowledge of cancer drug development and active engagement on social media.

2012 Chemotherapy Foundation Symposium

Daedalus — Mon, 29 Oct 2012 16:09:21 +0000

The 2012 Chemotherapy Foundation Symposium takes place at the Marriott Marquis in Times Square, New York City from November 7 – 10 and has presentations on new developments in cancer therapy.